R121919
| Title | Journal |
|---|---|
| Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. | Drug and alcohol dependence 20130301 |
| Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists. | Journal of medicinal chemistry 20121011 |
| Effects of CB1 and CRF1 receptor antagonists on binge-like eating in rats with limited access to a sweet fat diet: lack of withdrawal-like responses. | Physiology & behavior 20120910 |
| Depressive and cardiovascular disease comorbidity in a rat model of social stress: a putative role for corticotropin-releasing factor. | Psychopharmacology 20120701 |
| Synthesis and structure-activity relationships of pyrazolo[1,5-a]pyridine derivatives: potent and orally active antagonists of corticotropin-releasing factor 1 receptor. | Journal of medicinal chemistry 20120614 |
| Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles. | Bioorganic & medicinal chemistry letters 20111015 |
| Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist. | Journal of medicinal chemistry 20110623 |
| Persistent anxiolytic affects after chronic administration of the CRF₁ receptor antagonist R121919 in rats. | Neuropharmacology 20110601 |
| Lithium, but not fluoxetine or the corticotropin-releasing factor receptor 1 receptor antagonist R121919, increases cell proliferation in the adult dentate gyrus. | The Journal of pharmacology and experimental therapeutics 20110401 |
| [¹²⁵I]YP20: a novel radioligand specific for the extracellular domain of the CRF₁ receptor. | European journal of pharmacology 20101215 |
| Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties. | Bioorganic & medicinal chemistry letters 20101215 |
| Corticotropin releasing factor-induced amygdala gamma-aminobutyric Acid release plays a key role in alcohol dependence. | Biological psychiatry 20100501 |
| Consequences of chronic social stress on behaviour and vasopressin gene expression in the PVN of DBA/2OlaHsd mice--influence of treatment with the CRHR1-antagonist R121919/NBI 30775. | Journal of psychopharmacology (Oxford, England) 20090101 |
| 2-Arylpyrimidines: novel CRF-1 receptor antagonists. | Bioorganic & medicinal chemistry letters 20080815 |
| Restraint stress and ethanol consumption in two mouse strains. | Alcoholism, clinical and experimental research 20080501 |
| CRH-sub-1 receptor antagonists for the treatment of depression and anxiety. | Experimental and clinical psychopharmacology 20071201 |
| The CRF1 receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawal. | European journal of pharmacology 20070924 |
| The CRF1 receptor antagonist R121919 attenuates the neuroendocrine and behavioral effects of precipitated lorazepam withdrawal. | Psychopharmacology 20070601 |
| Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. | Biological psychiatry 20070101 |
| Facilitation of cardiac vagal activity by CRF-R1 antagonists during swim stress in rats. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20061201 |
| Dissociation between opioid and CRF1 antagonist sensitive drinking in Sardinian alcohol-preferring rats. | Psychopharmacology 20061201 |
| Impact of state of arousal and stress neuropeptides on urodynamic function in freely moving rats. | American journal of physiology. Regulatory, integrative and comparative physiology 20060601 |
| Glucocorticoid receptor and treatment of psychotic major depression. | Yao xue xue bao = Acta pharmaceutica Sinica 20051101 |
| Enduring, handling-evoked enhancement of hippocampal memory function and glucocorticoid receptor expression involves activation of the corticotropin-releasing factor type 1 receptor. | Endocrinology 20050901 |
| Analysis of the hormone-binding domain of steroid receptors using chimeras generated by homologous recombination. | Experimental cell research 20050815 |
| Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists. | Journal of medicinal chemistry 20050811 |
| The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. | Psychopharmacology 20050701 |
| Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core. | Journal of medicinal chemistry 20050616 |
| Identification of molecules potentially involved in mediating the in vivo actions of the corticotropin-releasing hormone receptor 1 antagonist, NBI30775 (R121919). | Psychopharmacology 20050601 |
| Corticotropin-releasing hormone-mediated induction of intracellular signaling pathways and brain-derived neurotrophic factor expression is inhibited by the activation of the endocannabinoid system. | Endocrinology 20050301 |
| Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. | European journal of pharmacology 20040919 |
| Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists. | Journal of medicinal chemistry 20040909 |
| Altered serotonergic neurotransmission but normal hypothalamic-pituitary-adrenocortical axis activity in mice chronically treated with the corticotropin-releasing hormone receptor type 1 antagonist NBI 30775. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20031201 |
| Synthesis and SAR of 8-arylquinolines as potent corticotropin-releasing factor1 (CRF1) receptor antagonists. | Bioorganic & medicinal chemistry letters 20031006 |
| Role of corticotropin-releasing factor receptors type 1 and 2 in modulating the rat adrenocorticotropin response to stressors. | Endocrinology 20030601 |
| The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. | The Journal of pharmacology and experimental therapeutics 20030201 |
| Corticotropin-releasing hormone modulators and depression. | Current opinion in investigational drugs (London, England : 2000) 20030101 |
| The high-affinity non-peptide CRH1 receptor antagonist R121919 attenuates stress-induced alterations in plasma oxytocin, prolactin, and testosterone secretion in rats. | Pharmacopsychiatry 20030101 |
| Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. | Journal of psychiatric research 20030101 |
| 3-Aryl pyrazolo[4,3-d]pyrimidine derivatives: Nonpeptide CRF-1 antagonists. | Bioorganic & medicinal chemistry letters 20020819 |
| Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20020801 |
| The CRH1 receptor antagonist R121919 attenuates stress-elicited sleep disturbances in rats, particularly in those with high innate anxiety. | Journal of psychiatric research 20020101 |
| Recent advances in the neurobiology of depression. | Psychopharmacology bulletin 20020101 |
| Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. | Journal of psychiatric research 20000101 |